(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 891.2K | +14% |
Gross Profit | 231.1K | - |
Cost Of Revenue | 660.1K | -6% |
Operating Income | -3.8MM | -9% |
Operating Expenses | 4MM | -5% |
Net Income | -1.1MM | -69% |
R&D | 935.8K | -0% |
G&A | 3.1MM | -7% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
- Project To Increase RNAP Manufacturing Capacity and Reduce Unit Costs of Goods - - Project Slated for Completion Coincident with Company's Planned Initiation of GMP Manufacturing for Linea™ DNA IVT Templates - STONY BROOK, NY and JUPITER, FL / ACCESSWIRE ...
STONY BROOK, NY / ACCESSWIRE / March 14, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, will showcase its Linea™ IVT and Linea™ DNA platforms at the 24th Annual World Vaccine Congress, which ...
Here is how Applied DNA Sciences (APDN) and Encore Wire (WIRE) have performed compared to their sector so far this year.
Applied DNA Sciences ( NASDAQ:APDN ) First Quarter 2024 Results Key Financial Results Revenue: US$891.2k (down 83% from...
Applied DNA Sciences, Inc. (NASDAQ:APDN) Q1 2024 Earnings Call Transcript February 9, 2024 Applied DNA Sciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and welcome to the Applied DNA Sciences Fiscal First Quarter 2024 Financial Results […]
Q1 2024 Applied DNA Sciences Inc Earnings Call
Applied DNA Sciences (APDN) delivered earnings and revenue surprises of 70.97% and 27.29%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
- Company On Track to Initiate First-Phase GMP Production Capacity for mRNA Critical Starting Materials During First Half of Calendar 2024, Projects Initial Facility Capacity to Enable up to $15 Million1 of Linea IVT Revenue2 Annually - - Conference ...
STONY BROOK, NY / ACCESSWIRE / February 5, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its first quarter fiscal ...
STONY BROOK, NY / ACCESSWIRE / February 2, 2024 /Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that it has closed its previously announced registered direct offering of its common stock ...